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Measurement of Plasma
Endothelin-1 in Experimental
Hypertension and in Healthy Subjects
Saad Abdel-Sayed, Juerg Nussberger, Jean-Franc¸ois Aubert,
Peter Gohlke, Hans Rudolf Brunner, and Noureddine Brakch
Background: Endothelin-1 is an endothelium-derived
potent vasoconstrictor peptide of 21 amino acids. To es-
tablish reference values in different models of hyperten-
sion and in human subjects an assay for plasma
immunoreactive endothelin-1 (ET-1) was optimized.
Methods: ET-1 is extracted by acetone from 1 mL of
plasma and subjected to a sensitive enzyme-linked immu-
nosorbent assay.
Results: The detection limit for plasma ET-1 is 0.05
fmol/mL. Mean recoveries of the 1, 2, 5, and 10 fmol of
ET-1 added to 1 mL of plasma were 66%, 75%, 85%, and
92%, respectively. Within- and between-assay coefficients
of variation were 12% and 10%, respectively. Assay
accuracy was demonstrated by consistent recoveries of
added ET-1 over the entire physiologic range of plasma
concentrations and by the linearity of ET-1 concentrations
measured in serially diluted plasma extracts (r 0.99). No
ET-1 was detected when albumin buffer was extracted
instead of plasma. Using this method, we found increased
ET-1 levels in plasma of three experimental rat models of
hypertension: stroke prone spontaneously hypertensive
rats (SP-SHR), deoxycorticosterone acetate-salt hyperten-
sive rats, and one kidney-one clip hypertensive rats. In
contrast, plasma ET-1 levels of SHR were half those of
normotensive Wistar rats. In two kidney-one clip hyper-
tensive rats, plasma ET-1 concentrations were not different
from those found in sham-operated control rats. Plasma
ET-1 concentrations of 37 healthy men were 0.85  0.26
fmol/ml (mean  SD).
Conclusions: The present assay reliably measures
ET-1 levels in rat and human plasma. It allows to discrim-
inate between different forms of hypertension with high or
low circulating levels of ET-1. Am J Hypertens 2003;16:
515–521 © 2003 American Journal of Hypertension, Ltd.
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T he endothelins are a family of 21-amino-acid pep-tides with vasoactive, inotropic, and mitogenicproperties. At present, three isopeptides, endothe-
lin-1, endothelin-2, and endothelin-3, each with distinct
genes and distributions in tissues, have been identified.1
Endothelin-1 appears to be the predominant isoform pro-
duced by the vascular endothelium; it acts mainly in a
paracrine fashion on vascular smooth muscle cells where it
causes long-lasting vasoconstriction.2
Recent research has accumulated evidence for the clin-
ical implications of endothelin. Plasma immunoreactive
endothelin-1 (ET-1) concentrations have been shown to be
of prognostic value in heart failure3 and acute myocardial
infarction.4 Moreover, ET-1 has been suggested to be a
marker for early reocclusion after percutaneous translumi-
nal coronary angioplasty,5 for coronary arteriosclerosis
and coronary endothelial dysfunction,6 for liver damage,7
and declining renal function.8 High plasma levels of ET-1
have been reported in different states of ischemia,9 hemo-
dialysis, and essential hypertension.10 Elevated ET-1 has
also been demonstrated during cardiac, liver, renal, and
bone marrow transplantation.11,12 A significant role of
ET-1 in the pathogenesis of cancer has recently been
suggested.13
Normal plasma concentrations of ET-1 are in the low
picomolar range.14–17 Sensitive methods are needed for ac-
curate measurement of this plasma peptide and for determi-
nation of differences in circulating levels of ET-1 in different
physiologic and pathophysiologic states. The exclusion of
cross-reacting material and related precursor or metabolite
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endothelin peptides present in plasma is required for specific
estimation of ET-1. Reported plasma concentrations of ET-1
in healthy human subjects vary considerably with mean val-
ues ranging between 0.1 and 5.0 fmol/mL.3 Even a low
detection limit of 0.2 fmol/mL may be insufficient without
exclusion of cross-reactions.14 Li et al16 could not find in-
creased circulating ET-1 levels in deoxycorticosterone ace-
tate-salt hypertensive (DOCA-salt) rats using antibodies
cross-reacting with endothelin-3 and big endothelin. Well-
performing assays may be challenged because of high normal
values if they use SepPak extraction without providing ex-
traction blanks, and antisera which cross-react 52% with
endothelin-3 and also with big endothelin.17
Careful sample handling to avoid in vitro artifacts and
reliable extraction procedures to limit variation of recoveries
are key elements required to obtain any meaningful quanti-
tation. In the present study, we evaluated and modified a
sensitive sandwich-enzyme immunoassay for plasma ET-1
based on commercially available materials. Preliminary ex-
periments according to the manufacturer’s protocol had pro-
vided unsatisfactory recoveries decreasing from 88% to 30%
when 2 and 10 fmol/mL of standard endothelin were added to
plasma. Sample handling, extraction procedures, and buffer
compositions had to be optimized to obtain reproducible
results in the physiologic range. Using the modified new
method we measured plasma ET-1 concentrations in normal
control rats and in five different models of hypertensive rats
(spontaneously hypertensive rats [SHR], stroke prone spon-
taneously hypertensive rats [SP-SHR], DOCA-salt, two kid-
ney-one clip [2K1C], one kidney-one clip [1K1C]), as well as
in healthy human subjects.
Methods
Blood Sampling
Five milliliters of blood were collected from the cubital
vein of supine healthy male volunteers. Two milliliters of
blood were collected from the femoral artery of conscious
rats through an indwelling catheter. Blood was immedi-
ately transferred into prechilled glass tubes (ice bath)
containing 0.054 mL of 15% tripotassium EDTA to
achieve a final plasma concentration of 7 mmol/L. Blood
was centrifuged at 4°C for 10 min at 1660 g. Plasma
aliquots of 1.2 mL were stored in polypropylene tubes at
20°C.
Extraction of ET-1 From Plasma
Endothelin is extracted from plasma as summarized in Fig.
1 (left panel). To 1 mL of plasma rapidly thawed under
cold water stream we add 1.5 mL of acetone/0.2 mol/L
HCl (87/13, v/v). After vigorous mixing for 1 min at room
temperature, the mixture is kept at 4°C for 18 h and
subsequently centrifuged at 1660 g for 30 min at 4°C. The
supernatant is dried under vacuum (Speed Vac, Savant,
Basel, Switzerland) and the dry extract is redissolved in
0.5 mL of borate buffer (0.05 mol/L, pH 8.3) containing
bovine serum albumin (Sigma, Buchs, Switzerland) at 5
g/L. Samples are vigorously vortexed for 1 min at room
temperature and subsequently centrifuged at 1660 g for 5
min at 4°C. Two aliquots of 200 L of supernatant (du-
plicates) are subjected to quantitative enzyme-linked im-
munosorbent assay (ELISA).
ELISA
The quantitation of ET-1 is performed according to the
protocol of the provider of the materials (Biomedica, Vi-
enna, Austria) using duplicate samples of 200 L of
plasma extract or standard ET-1 (Bachem, Bubendorf,
Switzerland) in assay buffer (Fig. 1, right panel). The
assay buffer is a 0.05-mol/L borate buffer at pH 8.3,
containing 0.26 mol/L sodium chloride, 5 g/L bovine
serum albumin, 0.2 g/L sodium azide, and 5% (v/v) Triton
X-100. The 200 L extract or standard samples are pipet-
FIG. 1. Left panel) Procedure of liquid phase extraction of endothelins from plasma before measurement of endothelin-1 by enzyme-linked
immunosorbent assay (ELISA). Right panel) Procedure of specific measurement of endothelin-1 by ELISA. BSA  bovine serum albumin.
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ted into the wells of a microtiter plate precoated with
polyclonal capture antibody recognizing the carboxyl end
of endothelin but excluding big endothelin (0.001%
cross-reaction). Fifty microliters of monoclonal detection
antibody recognizing specifically (amino-terminal) endo-
thelin-1 (and endothelin-2, but excluding endothelin-3) are
dissolved in borate buffer and added to all wells. The
microtiter plate is covered with plastic film and incubated
overnight (18 h) at room temperature. The contents of the
wells are discarded and the wells washed five times with
300 L washing buffer (0.1 mol/L phosphate, 0.1% [v/v]
Twin-20). Two hundred microliters of peroxydase conju-
gated third antibody (rabbit antimouse Fc) are added and
the microtiter plate is incubated under orbital shaking for
1 h at 37°C. Unbound conjugated antibody is then re-
moved and the wells are washed five times. Two hundred
microliters of tetramethylbenzidine substrate solution are
added and the microtiter plate is incubated in the dark at
room temperature for 30 min. Stop solution consisting of
50 L of 0.9% (v/v) sulfuric acid is added and the absor-
bance measured immediately at 450 nm with an ELISA
reader (Molecular Devices, Basel, Switzerland).
Assay Characteristics
Recovery Recoveries were determined by spiking nor-
mal human plasma with different amounts of exogenous
endothelin-1. Before acetone extraction, 0, 1, 2, 5, or 10
fmol (n  5 each) of exogenous endothelin-1 (Bachem) in
borate buffer was added to 1-mL aliquots of plasma of one
volunteer. The endogenous concentration of ET-1 (mean
 SD) was 0.84  0.10 fmol/mL. The difference between
total ET-1 and endogenous ET-1 was expressed as a
percentage of the added (exogenous) endothelin-1. All
results reported here are not corrected for recovery losses.
Precision and Accuracy Imprecision was defined by
the coefficient of variation (CV). Within-assay precision
was determined by seven repeated measurements within
the same assay. The between-assay CV were determined
by measuring the endothelin-1 concentration of two hu-
man plasmas in consecutive assays (n  7 and 8). The
specificity of the assay was tested by establishing standard
curves with synthetic pure endothelin peptides (Bachem)
in buffer (endothelin-1, endothelin-2, endothelin-3, big
endothelin-1); cross-reaction was defined as the ratio be-
tween concentrations of endothelin-1 and the analog en-
dothelin providing identical optical densities. Possible
interference caused by the extraction procedure was inves-
tigated by analyzing extracts of the borate buffer for ET-1
(buffer blank; n  2). The absence of nonspecific interfer-
ence in the ELISA was determined by serial dilution of
plasma extracts with borate buffer.
Normal Human Values Plasma ET-1 was measured in
37 healthy men in the supine position. The subjects were
20 to 35 years old.
Experimental Animals
Male Wistar rats and SHR of 8 weeks of age weighing 220
to 246 g were purchased from Iffa Credo (L’Arbresle,
France) and SP-SHR were from the Institute of Pharma-
cology in Kiel (Germany). Rats were housed in transparent
plastic cages in a quiet room at 22°C and maintained on
standard rat chow containing 0.22% sodium and 0.20%
potassium and tap water ad libitum. The Institutional An-
imal Care Committee approved the study protocols.
Twenty-four hours before blood sampling, rats were
anesthetized by inhalation of 2% halothane in oxygen.
Polyethylene (PE) catheters, consisting of PE-10 intravas-
cular segments welded to PE-50 tubing were inserted into
right femoral arteries for arterial blood pressure measure-
ments and blood sampling. The PE-50 tubing were
threaded under the skin and exteriorized at the back of the
neck. The rats were housed individually in plastic cages
and kept in a quiet place at 22°C.
On the study day, conscious rats were placed in a
plastic tube for partial immobilization. Mean arterial pres-
sure and heart rate were monitored after 20 min of rest,
using the Notocord computerized system (Paris, France).
Then 2 mL of arterial blood was collected and plasma was
stored as described.
2K1C Hypertension Male 6-week-old Wistar rats
weighing 160 to 170 g (n  15) were anesthetized using
2% halothane in oxygen. An incision was made in the left
abdomen, the left renal artery was isolated, and a Plexiglas
clip (0.20 mm gap) was placed around the left renal artery
(2K1C, n  7). In control rats, the clip was subsequently
removed (sham-operated, n  8). After a 3-week obser-
vation period, mean arterial blood pressure was measured
and blood samples were collected.
1K1C Hypertension Male 6-week-old Wistar rats
weighing 170 to180 g were used. To induce 1K1C hyper-
tension (n  9), a right nephrectomy was performed. The
left renal artery was clipped as described previously. Con-
trol rats were prepared by performing a unilateral nephrec-
tomy (sham-operated, n 10). After a 3-week observation
period, mean arterial blood pressure was measured and
blood samples were collected.
DOCA-Salt Hypertension Male 6-week-old Wistar
rats weighing 170 to 180 g (n  9) were uninephrecto-
mized under 2% halothane in oxygen anesthesia. A sili-
cone tube (Cole-Parmer Instrument Co., Vernon Hills, IL)
was prepared according to Wang et al,18 (28 mm length, 4
mm external diameter, 2.3 mm internal diameter; with 10
to 14 micropores of nearly 300 m diameter on the wall).
Each tube was filled with 80 mg of DOCA powder (Sigma
Chemical Co., St. Louis, MO) and a silicone tubing of 2
mm in length was inserted into each end of the DOCA
tube to keep the powder confined to the tube. This stopper
tubing had an external diameter of 2.3 mm and an internal
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diameter of 0.8 mm. One DOCA tube was implanted
subcutaneously to each rat. They received 1% saline to
drink. Rats became hypertensive and were studied 6 weeks
after implanting the tubes. Uninephrectomized rats receiv-
ing tap water served as controls (n  9).
Statistical Analysis
Results are presented as means  SD unless stated other-
wise. Regression analysis was calculated by the method of
least squares. Correlation coefficients for linear regression
are presented. The unpaired Student t test was used to
compare hypertensive rats with the controls. The signifi-
cance level was P  .05.
Results
Characteristics of Endothelin Assay
Fig. 2 shows the recoveries for acetone extraction of ET-1
from 1 mL of human plasma (mean  SD, n  5).
Unspiked plasma contained 0.84  0.10 fmol/mL ET-1 (n
 7). The mean recoveries were 66%, 76%, 86%, and
92% for added ET-1 at 1, 2, 5, and 10 fmol/mL, respec-
tively. With increasing ET-1 content of the plasma, the
precision of the measured ET-1 concentration increased.
Table 1 presents the within-assay coefficients of varia-
tion for multiple ET-1 measurements of five different
plasmas with ET-1 concentrations ranging from 1 to 10
FIG. 2. Recovery of increasing amounts of endothelin-1 added to
plasma. One milliliter of human plasma containing 0.84 fmol of
endogenous immunoreactive endothelin-1 was spiked with 0, 1, 2,
5, and 10 fmol of synthetic endothelin-1. Measured peptide concen-
trations are plotted after subtraction of endogenous endothelin-1.
Standard deviations were smaller than the size of the symbols.
Table 1. Within-assay coefficient of variation for
increasing plasma ET-1 concentrations
ET-1 (fmol/mL)* n CV%
0.84  0.10 7 11.9
1.49  0.07 5 4.7
2.33  0.08 5 3.4
5.17  0.13 5 2.5
9.94  0.05 5 0.5
ET-1  immunoreactive endothelin-1; CV  coefficient of variation.
* Mean  SD.
Table 2. Between-assay coefficient of variation for
two human plasmas
ET-1 (fmol/mL)* n CV %
1.02  0.08 8 7.8
1.22  0.12 7 9.8
Abbreviations as in Table 1.
* Mean  SD.
FIG. 3. Linearity of extract dilution. Endothelin was extracted from
two different human plasmas (upper and lower panels) and ex-
tracts were serially diluted before measurement of immunoreactive
endothelin-1 (ET-1) concentrations. The linearity of results ex-
cludes cross-reacting interferences.
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fmol/mL. These CV decreased with increasing concentra-
tions of ET-1 from 11.9% to 0.5%.
The between-assay coefficients of variation for two
human plasma samples are depicted in Table 2. They are
situated at 7.8% and 9.8%.
The detection limit was defined as the ET-1 content read
on the standard slope at three standard deviations above the
optical density found in the absence of ET-1. The detection
limit of the assay for 1 mL of plasma was 0.05 fmol/mL.
Assay accuracy is demonstrated by the close linear
relationship between ET-1 added to and recovered from
plasma (y  0.93x  0.24, r  0.99; Fig. 2) and by the
linearity of ET-1 concentrations measured in two different
serially diluted plasma extracts (Fig. 3) Taking the reac-
tion with ET-1 as 1.00, the cross-reactions with big ET-1,
with ET-2 and with ET-3 were 0.000006, 1.020, and
0.048, respectively. No ET-1-like material was detected
when the albumin-containing borate buffer was extracted
instead of plasma.
Plasma levels of ET-1 in normal human subjects were
0.85 0.30 fmol/mL (mean SD, n 37), ranging from
0.37 to 1.57 fmol/mL.
Rat Hypertension Models
Table 3 shows plasma ET-1 concentrations as well as
weight and mean arterial pressure of normotensive Wistar
rats and of five different rat models of hypertension. Nor-
motensive Wistar rats had plasma ET-1 levels of 0.7 to 2.1
fmol/mL. In SHR, plasma ET-1 levels were lower (P 
.01) and in SP-SHR, they were higher than in normoten-
sive Wistar rats (P  .001). Fig. 4 depicts blood pressure
and plasma ET-1 levels in surgically induced models of
hypertension. In hypertensive 1K1C rats, mean plasma
ET-1 was increased 32% compared to sham-operated uni-
nephrectomized rats (P  .002). The equally hypertensive
2K1C rats had plasma ET-1 levels that where not different
from their controls but tended to be decreased (11%; P
 not significant). The DOCA-salt hypertensive rats ex-
hibited 3.6-fold higher circulating ET-1 than normotensive
uninephrectomized controls (P  .001).
Discussion
Among the circulating endothelins, their precursors, and
metabolites, the 21-amino-acid vasoconstrictor isopeptide
endothelin-1 appears to play a predominant role.2 Its
plasma concentrations in the low picomolar range require
careful sample handling to avoid in vitro generation or
metabolization of the peptide, as well as a reliable extrac-
tion technique and sensitive methods to quantitate. Unlike
its original commercial protocol, the modified assay de-
scribed here fulfills these requirements. It enables accurate
measurement of human plasma levels and allows to dem-
onstrate differences in circulating ET-1 between various
rat models of hypertension.
From 1 milliliter of EDTA–plasma endothelins are
extracted into cold acetone during an extended (18 h)
period, whereas proteins and enzymes generating or me-
tabolizing ET-1 are precipitated. The procedure is charac-
terized by reasonably low CV and 50% recoveries of
physiologic plasma ET-1 concentrations. For higher
plasma ET-1 concentrations, mean recoveries are further
increased and the CV become very small (Table 1).
The specificity of our ET-1 measurement is provided by
the sandwich-type immunoassay. The capture antibody
excludes big endothelins, and the detection antibody hardly
recognizes endothelin-3 (5% cross-reaction), which only rep-
resents 10% of circulating endothelins; the fully cross-react-
ing endothelin-2 is virtually absent in plasma.19–22 The
absence of any interference is also confirmed by linearity of
measured ET-1 levels in serially diluted plasma extract (Fig.
3), because any cross-reacting material would disturb the
Table 3. Plasma immunoreactive endothelin-1 in different rat models of hypertension (mean  SD)
Rat Type n
Body
Weight (g)
Mean Arterial
Pressure (mm/Hg)
Immunoreactive Endothelin-1 (fmol/mL)
Arithmetic
Mean
Geometric
Mean Range
Two kidney rats
SHR 9 225  10 154  8† 0.64  0.08† 0.64 0.50–0.78
Wistar 9 230  10 117  9 1.20  0.78 1.24 0.77–2.08
SP-SHR 10 240  10 177  6* 1.64  0.13* 1.63 1.42–1.79
Wistar 10 246  11 119  13 1.17  0.35 1.13 0.73–1.90
2K1C 7 289  24 187  11§ 1.17  0.28 1.14 0.77–1.60
Sham 8 331  15 114  7 1.33  0.30 1.30 0.85–1.56
One kidney rats
1K1C 9 291  40 181  22§ 1.38  0.22‡ 1.36 1.03–1.54
Sham 9 309  19 116  9 1.00  0.07 0.99 0.89–1.09
DOCA-salt 8 251  31 197  19§ 2.57  1.02§ 2.38 1.32–4.02
Sham 7 356  13 120  6 0.60  0.38 0.41 0.05–1.21
SHR  spontaneously hypertensive rats; SP-SHR  stroke prone-spontaneously hypertensive rats; 2K1C  2 Kidney-1 clip Goldblatt
hypertensive rats; 1K1C  1 Kidney-1 clip hypertensive rats; DOCA-Salt  deoxycorticosterone acetate/saline rats.
* P  .01; † P  .001 v Wistar rats. ‡ P  .01; § P  .001 v sham-operated rats.
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linearity derived from a pure endothelin-1 standard
slope.19,21,22
Several findings demonstrate the accuracy of our ET-1
measurement. First, serial dilution of plasma extracts yield
perfectly linear endothelin-1 concentrations and the re-
gression slopes show practically no y-axis intercept (Fig.
3). This virtually excludes the presence in the assay of any
interfering or cross-reacting material. Second, buffer ex-
tracts do not contain any ET-1 and thus, exclude blank
interference due to extraction or washing procedures.
Third, repeat measurements of ET-1 concentrations in
different plasmas provide consistent results. Both within-
assay and between-assay CV are consistently below 12%
within the tested range.
The detection limit of the assay for plasma ET-1 is 0.05
fmol/mL. Normal human plasma levels of ET-1 are 0.4 to 1.6
fmol/mL. They are in agreement with low picomolar normal
values published by other investigators, who sometimes cor-
rected their results for recovery losses.14–17,23–27 Not surpris-
ing, among these established assays for ET-1, the highest
normal values were measured by assays which also included
some cross-reacting big endothelins or endothelin-3; in addi-
tion, nonspecific blank interference was never excluded.17,27
Using our assay method, we demonstrate increased
ET-1 levels in the plasma of three experimental rat models
of hypertension. Plasma ET-1 concentration was higher in
SP-SHR than in normotensive Wistar rats, and DOCA-salt
hypertensive rats exhibited four times higher ET-1 levels
than sham-operated control rats. This contrasts with the
findings of Li et al.16 They could not find increased cir-
culating ET-1 levels in DOCA-salt rats using antibodies
cross-reacting with endothelin-3 and big endothelin.16 Our
1K1C hypertensive rats showed a moderate increase in
ET-1 levels compared to sham-operated controls (Table
2). In contrast, the ET-1 level in the plasma of SHR was
only half the level of normotensive Wistar rats. Schiffrin et
al28 did not find such a difference between Wistar and
SHR, but they used the SepPak extraction method and
antiserum cross-reacting with big endothelin-1 and endo-
thelin-3 at 10% and 7%, respectively. In 2K1C Goldblatt
hypertensive rats, a renin-dependent model of hypertension,
no increase in plasma ET-1 was observed. These findings
complement and extend those reported by Schiffrin28,29 and
Sventek30 and their colleagues. These researchers demon-
strated an increased content of ET-1 and of preproendothe-
lin-1 mRNA in the vascular wall of SP-SHR, DOCA-salt,
and 1K1C hypertensive rats, but not in 2K1C or SHR hyper-
tensive rats. Thus, our modified extraction and quantitation
procedures of plasma ET-1 made it possible to measure
increased plasma ET-1 levels in some forms of hypertension
(SP-SHR, DOCA-salt, 1K1C), but not in other forms (2K1C,
SHR).
In conclusion, ET-1 concentration in 1 mL of plasma
can be reliably measured by acetone extraction and sub-
sequent ELISA. Normal plasma ET-1 levels in humans
and rats are in the low picomolar range. Significant dif-
ferences in plasma ET-1 levels are found in different
models of experimental hypertension.
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